MYGN Q4 2023 Earnings — Myriad Genetics, Inc. Revenue & Financial Results | Market Cap Arena

MYGNMyriad Genetics, Inc.

$487M

Q4 2023 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$197M+10.6% YoY

Gross Profit

$135M68.7% margin

Operating Income

-$31M-16.0% margin

Net Income

-$31M-15.9% margin

EPS (Diluted)

$-0.36

QoQ Revenue Growth

+2.4%

Cash Flow

Operating Cash Flow

-$55M

Free Cash Flow

-$68M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$363M

Stockholders' Equity

$783M

Cash & Equivalents

$132M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$197M	$178M	+10.6%
Gross Profit	$135M	$124M	+9.0%
Operating Income	-$31M	-$46M	+31.7%
Net Income	-$31M	-$42M	+26.2%

Geographic Segments

UNITED STATES

$443M91%

Non-US

$45M9%